Nasus Pharma Ltd.
NSRXHealthcare|Medical - Pharmaceuticals|IL
$2.82
-0.09 (-3.09%)
DCF Value
$0.06
Tangible Book / Share
$0.99
Cash / Share
$1.07
About
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Stock Price
-62.6%(1Y)
1M
-22.3%
3M
-18.5%
6M
-10.5%
YTD
-69.2%
1Y
-62.4%
3Y
-65.8%
5Y
-65.8%
Pipeline Summary
7 total trials5
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
Completed: 4Recruiting: 1By Invitation: 2
Active Trials (1)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
NCT07868861Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 1Recruiting
Enrollment: 12 participants
Key Facts
Market Cap$24.3M
Employees7
CEOBrendan O'Grady
IPO DateAug 13, 2025
Beta4.26
52-Week Range$1.98 – $9.5
Avg Volume16,689
ExchangeAMEX
Websitenasuspharma.com
Ownership
Float33.1%
Shares Outstanding8.6M
Recent Insider Trades
Elmaliah OrenOTHER
Jun 13, 202024,680 shares @ $1.23
Elmaliah OrenOTHER
Jan 17, 202527,460 shares @ $6.05
Rubin EyalOTHER
Sep 18, 20260 shares
O'Grady Brendan P.OTHER
Jul 27, 20260 shares
Teleman Dan BenjaminOTHER
Jul 22, 20260 shares
Peers
Recent News
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Sep 29, 2026 · globenewswire.com
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Sep 14, 2026 · globenewswire.com
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026 · globenewswire.com
Nasus Pharma Announces Transition of Chief Financial Officer
Aug 19, 2026 · globenewswire.com
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Aug 17, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:24 AM